Palatin Technologies, Inc. announced that it has entered a strategic partnership with UpScriptHealth. Under terms of the agreement, UpScriptHealth will make Vyleesi available to the hundreds of thousands of patients in its proprietary Women's Telehealth Platform. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | +3.91% | +6.29% | -53.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.27% | 30.01M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.68% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- PTN Stock
- News Palatin Technologies, Inc.
- Palatin Technologies, Inc. Announces Direct-To-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi